1 |1 | Countries using and planning to introduce IPV and the global status of bOPV registration

2 |2 | Countries using and planning to introduce IPV November 2015 status report This slide deck provides a summary per country on the status of planning for the introduction of Inactivated Poliomyelitis Vaccine (IPV). It also includes a summary of the global status of national registration of bivalent Oral Polio Vaccine (bOPV), in preparation for the switch from trivalent OPV (tOPV) to bOPV. Information here is updated monthly based on information shared by WHO and UNICEF Regional Offices. Please contact with any questions or updates on this Definitions Formal decision to introduce: The country has documentation of its decision to introduce IPV which has been verified by the relevant WHO Regional Office, or for GAVI eligible countries, a complete application for IPV has been submitted to the GAVI Secretariat. Intent to introduce: The country has informally indicated that it plans to introduce IPV, e.g. planning an application to GAVI, or by requesting technical assistance to develop an IPV introduction plan. Tracking these decisions and informal intents provide an indication of the global trend towards meeting the targets of the Polio Eradication and Endgame Strategic Plan.

3 |3 | Countries using IPV vaccine to date and formal decision to introduce Since January 2013, the following countries have introduced IPV: Kazakhstan, Peru & Singapore (July 2013); Micronesia (August 2013); Libya (April 2014); Albania & Panama (May 2014); Nepal & Tunisia (September 2014); Philippines (October 2014); China (December 2014); Comoros, Senegal & Serbia (January 2015); Colombia & Nigeria (February 2015); Bangladesh & Maldives (March 2015); DR Congo, DPR Korea & The Gambia (April 2015); Madagascar (May 2015); Cote d'Ivoire, Grenada, Kiribati, Morocco, St Vincent and the Grenadines & Sudan (June 2015); Bhutan, Cameroon, Niger, Pakistan, Philippines & Sri Lanka (July 2015); Benin, Chad, Papua New Guinea, The Former Yug. Rep. of Macedonia (August 2015); Afghanistan, CAR, Dominica, Guyana, Iran, Jamaica, Seychelles & Solomon Islands (September 2015); Bahamas, Lao People's Dem Rep, Nauru, Samoa (October 2015); Botswana, Guinea, Tuvalu & Yemen (November 2015) Data source: WHO/IVB Database, as of 06 November 2015 Map production Immunization Vaccines and Biologicals (IVB), World Health Organization Date of slide: 6 November 2015 The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO All rights reserved. Introduced to date (119 countries or 61%) Formal commitment to introduce in 2015 (42 countries or 22%) Introduction delayed to 2016 due to global IPV vaccine shortage (33 countries or 17%) Not available Not applicable

4 |4 | Countries using IPV vaccine to date and introductions planned according to Gavi eligibility status Data source: WHO/IVB Database, as of 06 November 2015 Map production Immunization Vaccines and Biologicals (IVB), World Health Organization Date of slide: 6 November 2015 The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO All rights reserved. Introduced to date (119 countries or 61%) Gavi countries with formal commitment to introduce in (45 countries or 23%) Non Gavi countries with formal commitment to introduce in (30 countries or 15%) Not applicable Since January 2013, the following countries have introduced IPV: Kazakhstan, Peru & Singapore (July 2013); Micronesia (August 2013); Libya (April 2014); Albania & Panama (May 2014); Nepal & Tunisia (September 2014); Philippines (October 2014); China (December 2014); Comoros, Senegal & Serbia (January 2015); Colombia & Nigeria (February 2015); Bangladesh & Maldives (March 2015); DR Congo, DPR Korea & The Gambia (April 2015); Madagascar (May 2015); Cote d'Ivoire, Grenada, Kiribati, Morocco, St Vincent and the Grenadines & Sudan (June 2015); Bhutan, Cameroon, Niger, Pakistan, Philippines & Sri Lanka (July 2015); Benin, Chad, Papua New Guinea, The Former Yug. Rep. of Macedonia (August 2015); Afghanistan, CAR, Dominica, Guyana, Iran, Jamaica, Seychelles & Solomon Islands (September 2015); Bahamas, Lao People's Dem Rep, Nauru & Samoa (October 2015); Botswana, Guinea, Tuvalu & Yemen (November 2015) Not available

5 |5 | 75 countries introducing IPV between 5 November 2015 and September 2016 Tier 1 countries are countries with cVDPV2 transmission or cVDPV2 reported since 2000 & WPV endemic countries Tier 2 countries are countries with cVDPV 1/3 since 2000 or large /medium size countries with DTP3 coverage <80% in the past 3 years as per WUENIC Source: WHO/UNICEF database as at 06 November 2015 Nov-15Dec-15Jan-16Feb-16Apr-16After April-16 AlgeriaBelizeEquatorial GuineaAzerbaijanArmeniaAngola Antigua and BarbudaBoliviaMali Cabo VerdeBurkina Faso ArgentinaCambodiaSaint Kitts and Nevis DjiboutiEritrea BarbadosEcuadorUganda EgyptGhana BurundiEl Salvador Guinea-BissauIndonesia ChileFiji LesothoKyrgyzstan CongoGabon Sao Tome & PrincipeLiberia Cook IslandsGeorgia SwazilandMalawi CubaGuatemala Mongolia Dominican RepublicHonduras Rep. of Moldova EthiopiaIraq Rwanda HaitiMyanmar Sierra Leone IndiaParaguay Tajikistan KenyaThailand Togo MauritaniaTimor-Leste Turkmenistan MauritiusTrinidad and Tobago United Rep. of Tanzania MozambiqueVenezuela Uzbekistan Namibia Viet Nam Nicaragua Zambia Saint Lucia Zimbabwe Somalia South Sudan Suriname Tonga Vanuatu

6 |6 | Tier 1 and 2 Countries using IPV vaccine to date and formal decision to introduce Tier 1 countries are countries with cVDPV2 transmission or cVDPV2 reported since 2000 & WPV endemic countries Tier 2 countries are countries with cVDPV 1/3 since 2000 or large /Medium size countries with DTP3 coverage <80% in the past 3 years as per WUENIC Country Tier classification was updated on 15 October 2015 Data source: WHO/IVB Database, as of 06 November 2015, based on 36 tier 1 & 2 countries Map production Immunization Vaccines and Biologicals (IVB), World Health Organization Date of slide: 6 November 2015 The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO All rights reserved. Introduced to date (15 countries or 42%) Formal commitment to introduce in 2015 (16 countries or 44%) Not Applicable / Not Available / Not Tier 1 or 2 countries(158 countries ) Formal commitment to introduce in 2016 (5 countries or 14%) Since January 2013, the following Tier 1 and 2 countries have introduced IPV: The Philippines (October 2014), China (December 2014), Nigeria (February 2015), DR Congo (April 2015), Madagascar (May 2015), Cameroon, Niger and Pakistan (July 2015); Benin, Chad and Papua New Guinea (August 2015); Afghanistan and CAR (September 2015); Lao People's Democratic Republic (October 2015); Guinea & Yemen (November 2015)

7 |7 | Middle Income Countries using IPV vaccine to date and formal decision to introduce Data source: WHO/IVB Database, as of 06 November 2015 based on 100 middle income countries (MIC) as per last World Bank classification Map production Immunization Vaccines and Biologicals (IVB), World Health Organization Date of slide: 6 November 2015 The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO All rights reserved. Introduced to date (54 countries or 54%) Formal commitment to introduce in 2015 (28 countries or 28%) Formal commitment to introduce in 2016 (18 countries or 18%) Since January 2013, the following MIC have introduced IPV: Kazakhstan (July 2013); Peru (July 2013); Libya (March 2014); Albania (May 2014); Panama (July 2014); Tunisia (September 2014); Philippines (October 2014); China (December 2014); Senegal (January 2015); Serbia (January 2015); Colombia (February 2015); Maldives (March 2015) and Cote d'Ivoire, Kiribati, Morocco, St Vincent and the Grenadines & Sudan (June 2015); Bhutan, Cameroon, Pakistan & Sri Lanka (July 2015); Papua New Guinea & the former Yugoslav Rep. of Macedonia (August 2015); Dominica, Guyana, Iran, Jamaica & Solomon Islands (September 2015); Lao People's Democratic Rep & Samoa (October 2015); Botswana, Tuvalu & Yemen (November 2015) Not available / Not applicable / Non MIC countries

8 |8 | IPV introduction status and planned introduction by quarter by the end of 2015 Data source: WHO/IVB Database, as of 04 November 2015 Map production Immunization Vaccines and Biologicals (IVB), World Health Organization Date of slide: 4 November 2015 The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO All rights reserved. Introduced to date (119 countries or 61%) (42 countries or 22%) Introduction planned in Q Introduction delayed to 2016 due to global IPV vaccine shortage (33 countries or 17%) Not applicable Not available Since January 2013, the following countries have introduced IPV: Kazakhstan, Peru & Singapore (July 2013); Micronesia (August 2013); Libya (April 2014); Albania & Panama (May 2014); Nepal & Tunisia (September 2014); Philippines (October 2014); China (December 2014); Comoros, Senegal & Serbia (January 2015); Colombia & Nigeria (February 2015); Bangladesh & Maldives (March 2015); DR Congo, DPR Korea & The Gambia (April 2015); Madagascar (May 2015); Cote d'Ivoire, Grenada, Kiribati, Morocco, St Vincent and the Grenadines & Sudan (June 2015); Bhutan, Cameroon, Niger, Pakistan, Philippines & Sri Lanka (July 2015); Benin, Chad, Papua New Guinea, The Former Yug. Rep. of Macedonia (August 2015); Afghanistan, CAR, Dominica, Guyana, Iran, Jamaica, Seychelles & Solomon Islands (September 2015); Bahamas, Lao People's Dem Rep, Nauru, Samoa (October 2015); Botswana, Guinea, Tuvalu & Yemen (November 2015)

9 |9 | Overview of Global birth cohort by IPV status/tier (100% = million births in 2015) Data source: WHO/IVB Database, as of 06 November 2015 and United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision.

10 | bOPV registration status for routine immunization Approval for use (109 countries or 74%) Review in progress (21 countries or 14%) Pending submission (14 countries or 9%) Focus country - Belarus Not available/ non switch countries Not applicable (switch area territories) Data source: WHO/IVB Database, as of 06 November 2015 based on 148 OPV user countries and 7 Territories Map production Immunization Vaccines and Biologicals (IVB), World Health Organization The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO All rights reserved. (1 country or 1%) (46 countries) + 3 countries switching from tOPV to IPV Date of slide: 6 November 2015